On April 1, 2026, the Polish Ministry of Health will unveil an updated list of reimbursed medications, reflecting ongoing efforts to improve healthcare access and affordability in the country. This new list will include 16 newly reimbursed therapies, with a notable focus on oncology—14 out of the 16 new therapies target various forms of cancer. Additionally, two therapies will address non-cancerous conditions, marking a broadening of the types of treatments covered under Polish health insurance.

Several of the newly introduced therapies will be specialized for rare diseases, showcasing an increasing recognition of the need to cater to patients with unique health challenges. Among the 16 therapies, 15 will be included in existing medication programs, while one will be directly available for pharmacy reimbursement. This decision aligns with global trends where health systems aim to integrate advanced treatments and reduce out-of-pocket expenses for patients.

As these changes take effect, it will be crucial for healthcare providers and pharmacists to stay informed about the new reimbursement rules and ensure patients have access to these vital therapies. Stakeholders within the health sector will undoubtedly monitor the impact of these changes on treatment accessibility and overall public health outcomes in Poland, as the government continues to emphasize healthcare reforms and the expansion of medical coverage for its citizens.